Q-linea AB (publ) (QLINEA) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome, everyone. Thank you for joining this presentation of Qlinia's 2024 year-end report. This is Stuart Gander speaking here, CEO of Qlinia, and I have beside me Krister, our CFO. So just a quick note, obviously, regarding the forward-looking statements for this presentation, and we'll move straight into the agenda. So we wanted to do a few things today. So firstly, just reflect a little bit on what has been a year of great excitement, I would say, for the industry and certainly for our sector, a lot of developments. So we'll reflect a little bit on that and those who have been involved in moving things forward and then give a little bit of the status of the race, so to speak, now that we see the Rapid AST sector moving forward and what you as investors can expect for 2025 and beyond. So try to give a little bit of flavor of that. I will then hand it over to Christo who walked through a financial update and then we will have an open forum for questions. So a few things to make sure you take away if you log off after this slide would like to land basically on four key messages, right? So the first is that there is clear evidence that the global rapid AST race is now on in earnest. We see that commercial activity is ramping up across the key geographies. We'll give some more flavor there. And let's say the next generation Rapid AST instruments of which the ASTAR is, we would say, the leader in the field. We are now seeing placements of those instruments into clinical environments. So I would also add to that that we see evidence that Qlinia is the clear track leader. both in terms of placements of instruments and the coverage of patients so far associated with those instruments, and also crucially on the thought leadership side with more clinical evidence emerging ...